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Copyright © 2008 JCBN Summary To determine the effects of combined supplementation with chromium (Cr) and
vitamins C and E on oxidative stress in type 2 diabetes, adult subjects with HbA1c >8.5%.
Subjects (n = 30) in this randomized, double blind, placebo-control study were divided into
three groups (placebo, Cr or Cr + C + E) on daily treatment. The Cr group received 1000 μg
of Cr (as Cr yeast); the Cr + C + E group received Cr (1000 μg as Cr yeast) together with
vitamins C (1000 mg) and E (800 IU); and, a control group received a placebo. Baseline plasma
Cr levels were not significant differences comparing the supplementation and placebo groups.
Thiobarbituric acid reactive substances (TBARS) and total antioxidative status (TAS) were
also not significant different. Following the 6-month study period, the plasma TBARS levels,
fasting glucose, HbA1c and insulin resistance were significantly decreased in the Cr and
Cr + C + E groups, but not for the placebo group. Plasma TAS and glutathione peroxidase
were significantly higher for Cr and Cr + C + E groups relative to the placebo group. These
findings suggest that Cr supplementation alone and combined of Cr together with vitamins C
and E was effective for minimization of oxidative stress and improvement of glucose
metabolism in type 2 DM patients.
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Introduction
It is believed that diabetes is associated with increased
oxidative stress as increased blood concentrations of
thiobarbituric acid reactive substances (TBARS), a measure
of lipid peroxidation, have been reported [1, 2]. Oxygen-
derived radicals and reactive oxygen species are known to
attack cell membranes, resulting in the propagation of lipid
peroxidations.
Oxidative damage due to free radicals is associated with
vascular disease in people with type 1 and type 2 diabetes
mellitus (DM) [3, 4]. There are several potential sources of
free radical production in diabetics, including autoxidation
of plasma glucose (1), leucocyte activation, and increased
transition metal bioavailability [5]. The total antioxidant
status (TAS) in type 1 or 2 DM is lower than that of age-
matched controls, a finding which might be attributable to
lower levels of vitamin C, vitamin E [4, 6, 7], or other factors
including micronutrients in blood [8–12].
Anderson et al. [11, 13] have reported beneficial effects for
supplemental Cr on plasma glucose and related variables in
type 2 DM patients. Accompanying these data, there are other
studies, the results of which suggest that Cr also improves
cellular antioxidant capacity in rats [14–17]. Therefore,
restoring Cr status in individuals with type 2 DM may
counteract the deleterious effects of oxidative stress and help
prevent complications associated with diabetes [11, 13, 18].M.-H. Lai
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Vitamin E is considered the most important lipid-soluble
exogenous antioxidant in humans. Vitamin C serves as an
antioxidant, directly by scavenging aqueous peroxyl radicals,
and indirectly by regenerating reduced vitamin E [19].
Vitamins C and E defend against the damaging effects of
high oxidative stress in diabetes sufferers through nonenzy-
matic and autoxidative glycosylation, and reduction of
metabolic stress [20, 21].
In Taiwan, there has been a five-fold increase in mortality
from DM-related complications in the last 20 years. For type
2 DM, there is a high incidence of oxidative complications,
such as retinopathies, glomerulopathies, and vascular
complications. According to our previous study find that Cr
supplementation was an effective treatment strategy to
minimize increased oxidative stress in type 2 diabetes
mellitus patients whose HbA1c level was >8.5%, but the
effects of supplementation with Cr combined with the
vitamins C and E are unknown. Therefore, the present study
was conducted in Taipei to determine the effects of supple-
mentation with Cr combined with the vitamins C and E,
comparing the variables associated with oxidative stresses
and glucose homeostasis in a sample of patients with
severely hyperglycemic diabetes.
Materials and Methods
Subjects
Our sample of volunteers were adult males and females
under 56 years of age who had been diagnosed with diabetes
at least 5 years previously (fasting glucose >8.5 mmol/L and
HbA1c >8.5%). Key exclusion criteria included: pregnancy
and lactation; trace element and vitamin supplementation in
the preceding 3 months; ongoing gastric or diuretic treat-
ment; acute renal failure (creatinine <120 μmol/L); and,
recent surgery or acute infection. And individuals with
chronic kidney, liver, pulmonary or cardiac disease, smoking,
alcoholism were eliminated. Patients were enrolled from
Taipei Medical University Hospital. Approval was obtained
from the Human Studies Review Board of Taipei Medical
University Hospital. Patients were fully informed with
respect to the purpose of the study, were free to ask questions
throughout the investigation, and signed an informed
consent form witnessed by one of the investigators prior to
participation. Subjects (n = 30) in this randomized, double
blind, placebo-control study were assigned to one of three
groups (placebo, Cr or Cr + C + E) based on supplementa-
tion. Patients in each group were supplemented daily with a
placebo, or with 1000 μg Cr as yeast chromium (III), alone
or combined with 1000 mg vitamin C and 800 IU vitamin E
(Westar Nutrition Corp., Costa Mesa, CA). The quantity of
chromium was verified by chemical analysis. The subjects’
fasting-glucose concentrations were >8.5 mmol/L. All
subjects complete the 6-month study. All volunteers used
Metformim, Glibenclamide, Glipiazide, Gliclazide to control
their diabetes, and medication dosages remained the same
throughout the 6-month study. All the volunteers were
advised to maintain their normal dietary and exercise habits
during the study. Each month volunteers were asked to
return any unused supply to measure their daily compliance.
Subjects were also questioned with respect to any possible
side effects and their subjective assessment of compliance.
Subjects were requested to record dietary intake,
including time, place, types of food or ingredients, cooking
methods, and amounts at baseline and 6th month. “The
Common Food Nutrition Chart in Taiwan” issued by the
Department of Health, Taiwan, ROC was used as a reference
to help subjects record the data. The dietary data of these
subjects were collected by a 24-h dietary recall for three
consecutive days (include a no-week day) and was analyzed
by the food composition software (Institute of Biomedical
Sciences, Academia Sinica, Taipei, Taiwan, ROC) during
the study.
Analytical methods
Blood samples were drawn after an overnight fast at the
beginning of the study and after 6 months of daily supple-
mentation. The blood was taken from the antecubital vein
and collected in a Vacutainer trace element-free tube
(Becton-Dickinson, NJ). Urine samples were collected in
100-mL polypropylene specimen containers (Falcon, OH)
and stored at −20°C. All samples were run prior to the
breaking of the code, which was not available to the
investigators until completion of all the samples. Blood and
urinary Cr levels were determined using a Hitachi Z-5000
polarized Zeeman atomic absorption spectrophotometer
using standard electrothermal graphite furnace techniques
[22]. The in-house urinary sample was assayed at least twice
a day (for control checking) to confirm the accuracy of the
urinary Cr analysis [23].
Plasma samples and erythrocytes were stored at −70°C
prior to batch analyses. The autoanalyzer system (Hitachi-
7170; Hitachi Ltd, Tokyo, Japan) and diagnostic kits (Shino,
Tokyo, Japan) were used to determine plasma glucose
concentrations; diagnostic kits (WAKO, Osaka, Japan) were
used to determine plasma aspartate aminotransferase (AST),
alanine aminotransferase (ALT), creatinine and blood urea
nitrogen (BUN) concentrations. HbA1c level was assayed
with the HbA1c kit (Bayer, Kernersville, NC); the insulin kit
(DPC, LA) was used for insulin analysis.
Plasma TBARS levels were determined for assay of
malondialdehyde and thiobarbituric acid complex [24] by
fluorometry kit after extraction with n-butanol. The TAS
was determined for assay of the peroxidation rate through
fluorescence loss of the protein R-phycoerythrin induced by
2,2'-azobis(2-amidinopropane) dihydrochloride [25]. The
lag phase was compared to that of 6-hydroxy-2,5,7,8-Antioxidative and Insulin Resistance Improvement of Cr, Vitamin C and E
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tetramethylchroman-2-carboxylic acid (Trolox).
Red blood cell catalase activity was measured spectro-
photometrically by the absorbance change at 240 nm [26].
Superoxide dismutase activity was determined according to
the method of McCord and Fridovich [27]. Glutathione
peroxidase activity was measured according to the method
of Lawrence and Burk [28]. Activities were calculated in
units per milligram of protein to normalize differences
between control and diabetic blood. The Lowry method
was used for protein determination [29]. Insulin resistance
was calculated using the homeostasis model assessment
(HOMA) index [30].
Statistical analysis
Analysis of variance was used for statistical analysis of
the data. Individual means were compared using unpaired
t tests (SAS, SAS Institute, Cary, NC). Values are expressed
as mean ± SD. Group means were considered significantly
different at p<0.05.
Results
Effects of supplementation on anthropometric and labora-
tory variables
The group means for age, body mass index (BMI), and
blood levels of ALT, AST, creatinine and BUN were shown
in Table 1. There were no significant differences at baseline
and after 6 months of supplementation. In addition, we also
compared these variables between three groups at the same
time-point. No remarked differences were observed. These
data showed that there were no obvious differences of the
organs functions in these three groups. The levels of ALT,
AST, creatinine and BUN were within normal range.
Dietary data in 24-h dietary recall during the experiment
The intake of energy, carbohydrate, protein, fat, vitamin C
and vitamin E were shown in Table 2. There were no
significant differences at baseline and after 6 months of
supplementation. In addition, no remarked differences were
observed between three groups at the same time-point.
Effects of supplementation on blood glucose and insulin
variables
As shown in Table 3, levels of fasting glucose, HbA1c
and insulin were not significantly different at baseline.
Differences were noted, however, comparing the initial and
post-treatment levels of fasting glucose, HbA1c and insulin
resistance index. For the Cr group, fasting glucose, HbA1c
and insulin resistance index decreased significantly (p<0.05)
from 12.5 ± 0.5 to 11.1 ± 0.4 mmol/L and from 10.2 ± 0.5 to
Table 1. Effects of 6 months of chromium or combined chromium with vitamins C and E supplementation on anthro-
pometric and laboratory variables
1. Values are the mean ± SD.
2. “*” means significant difference between the placebo group and the Cr or Cr + C + E group.
3. AST: aspartate aminotransferase.
4. ALT: alanine aminotransferase.
Placebo (n =1 0 ) C r  ( n =1 0 ) C r+C+E  ( n =1 0 )
Men/women (n) 5/5 4/6 5/5
Age (years) 50.5 ± 1.9 53.2 ± 2.0 51.5 ± 1.7
Body mass index (BMI; kg/m2)
Baseline 25.8 ± 0.8 25.7 ± 0.9 25.7 ± 0.6
6 months 25.7 ± 0.7 25.6 ± 0.8 25.7 ± 1.0
Blood AST (IU/L)
Baseline 25.7 ± 2.4 24.8 ± 3.3 25.1 ± 2.5
6 months 25.4 ± 3.1 24.1 ± 2.4 25.9 ± 3.2
Blood ALT (IU/L)
Baseline 31.2 ± 2.8 29.1 ± 4.4 30.4 ± 2.4
6 months 32.1 ± 3.4 29.9 ± 2.7 30.8 ± 3.5
Blood creatinine (µmol/L)
Baseline 70.7 ± 8.8 70.7 ± 10.2 71.1 ± 8.6
6 months 70.4 ± 9.8 70.6 ± 8.9 70.9 ± 9.5
Blood urea nitrogen (mmol/L)
Baseline 5.1 ± 0.4 5.4 ± 0.5 5.3 ± 0.5
6 months 5.4 ± 0.5 5.4 ± 0.4 5.5 ± 0.5M.-H. Lai
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9.5 ± 0.2% and 8.1 ± 0.9 to 6.9 ± 0.7, respectively. Analogous
significantly decreases (p<0.05) for the Cr + C + E group
were 12.2 ± 0.5 to 11.0 ± 0.5 mmol/L and 10.0 ± 0.5 to
9.3 ± 0.5% and 8.1 ± 0.8 to 6.3 ± 0.9, respectively.
Effects of supplementation on blood and urinary Cr
Baseline levels of plasma Cr were not significantly
different demonstrated comparing the supplementation and
placebo groups. After 6 months of Cr or Cr + C + E supple-
mentation, the levels of plasma Cr were significantly
Table 2. Average daily intake of calorie, carbohydrate, protein, fat, vitamin C and vitamin E in 24-h dietary
recall during the experiment.
1. Values are the mean ± SD.
2. “*” means significant difference between the placebo group and the Cr or Cr + C + E group.
Placebo (n =1 0 ) C r  ( n =1 0 ) C r+C+E  ( n =1 0 )
Energy (kcal)
Baseline 1625 ± 147 1727 ± 215 1684 ± 261
6 months 1607 ± 226 1691 ± 305 1618 ± 279
Carbohydrate (g)
Baseline 225.1 ± 19.3 239.8 ± 33.8 230.4 ± 42.7
6 months 215.8 ± 23.1 248.7 ± 44.3 245.5 ± 35.2
Protein (g)
Baseline 53.9 ± 6.1 55.6 ± 7.2 51.1 ± 5.4
6 months 50.2 ± 5.6 56.9 ± 6.7 53.8 ± 8.5
Fat (g)
Baseline 58.4 ± 7.6 63.2 ± 5.2 61.5 ± 7.3
6 months 55.5 ± 8.7 59.4 ± 6.3 57.4 ± 6.2
Vitamin C (mg)
Baseline 95.0 ± 19.2 105.2 ± 15.9 99.7 ± 16.5
6 months 90.2 ± 23.6 104.3 ± 16.1 105.1 ± 21.4
Vitamin E (IU)
Baseline 300 ± 24 284 ± 20 296 ± 32
6 months 312 ± 36 288 ± 24 296 ± 28
Table 3. Effects of 6 months of chromium or combined chromium with vitamins C and E supplementation
on blood glucose and insulin variables
1. Values are the mean ± SD.
2. “*” means significant difference between the placebo group and the Cr or Cr + C + E group.
3. Insulin resistance index (HOMA-IR) = fasting blood glucose (mmol/L) × fasting serum insulin (μU/mL)/22.5
Placebo (n =1 0 ) C r  ( n =1 0 ) C r+C+E  ( n =1 0 )
Fasting glucose (mmol/L)
Baseline 12.25 ± 0.93 12.52 ± 0.51 12.24 ± 0.45
6 months 12.23 ± 0.43 11.12 ± 0.42* 11.04 ± 0.53*
HbA1c (%)
Baseline 10.1 ± 0.4 10.2 ± 0.5 10.0 ± 0.5
6 months 10.2 ± 0.4 9.5 ± 0.2* 9.3 ± 0.5*
Insulin (pmol/L)
Baseline 108.38 ± 16.50 103.58 ± 12.19 106.2 ± 11.11
6 months 120.72 ± 7.12 98.74 ± 9.55* 92.07 ± 8.67*
Insulin resistance index
Baseline 8.3 ± 0.9 8.1 ± 0.9 8.1 ± 0.8
6 months 9.2 ± 0.8 6.9 ± 0.7* 6.3 ± 0.9*Antioxidative and Insulin Resistance Improvement of Cr, Vitamin C and E
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increased (p<0.05) in the treatment groups compared to
placebo (Table 4). The baseline levels of urinary Cr were
not significantly different for all groups, increasing about
five-fold after Cr and Cr + C + E supplementation, respec-
tively (Cr, Cr + C + E>placebo; Table 4).
Effects of supplementation on blood TBARS and TAS
Mean baseline TBARS levels were 5.43, 5.42 and
5.52 μmol/L for the placebo, Cr, and Cr + C + E groups,
respectively. They were not statistically different at baseline
After 6 months of supplementation; the mean plasma
T B A R S  l e v e l s  f o r  t h e  p l a c e b o ,  C r  a n d  C r+C+E  g r o u p s
were 5.58, 4.41, and 3.60 μmol/L, respectively. The
differences between placebo and Cr, Cr + C + E groups
were significant (p<0.05). After 6 months of supplementa-
tion, plasma TBARS levels decreased significantly in
Cr + C + E groups compare to Cr alone. Baseline plasma
TAS levels were 1.10, 1.14 and 1.11 mmol/L for the placebo,
Cr and Cr + C + E groups, respectively, rising to 1.11, 1.27,
and 1.31 mmol/L, after 6 months of placebo, Cr or
Cr + C + E supplementation. Plasma TAS levels signifi-
cantly increased for the Cr and Cr + C + E groups relative to
that in the placebo group (Table 5).
Effects of Cr or Cr + C + E supplementation on antioxidant
enzyme activity
The baseline activity of antioxidant enzymes, such as
superoxide dismutase, glutathione peroxidase and catalase,
were not significantly different demonstrated comparing the
supplementation and placebo groups. After 6 months of Cr
Table 4. Effects of 6 months of chromium or combined chromium with vitamins C and E supplementation on blood
and urinary chromium
1. Values are the mean ± SD.
2. “*” means significant difference between the placebo group and the Cr or Cr + C + E group.
Placebo (n =1 0 ) C r  ( n =1 0 ) C r+C+E  ( n =1 0 )
Blood Cr (µg/dL)
baseline 0.16 ± 0.02 0.18 ± 0.07 0.18 ± 0.08
6 months 0.15 ± 0.05 0.57 ± 0.15* 0.58 ± 0.18*
Urinary Cr (ng/mg of creatinine)
baseline 0.21 ± 0.05 0.17 ± 0.02 0.18 ± 0.02
6 months 0.25 ± 0.05 0.95 ± 0.24* 0.93 ± 0.17*
Table 5. Effects of 6 months of chromium or combined chromium with vitamins C and E supplementation on
markers of oxidative stress
1. Values are the mean ± SD.
2. “*” means significant difference between the placebo group and the Cr or Cr + C + E group.
3. “**” means significant difference between the Cr group and the Cr + C + E group.
Placebo (n =1 0 ) C r  ( n =1 0 ) C r+C+E  ( n =1 0 )
TBARS (µmol/L)
Baseline 5.43 ± 0.16 5.42 ± 0.11 5.52 ± 0.11
6 months 5.58 ± 0.09 4.41 ± 0.10* ** 3.60 ± 0.07* **
TAS (mmol/L)
Baseline 1.10 ± 0.04 1.14 ± 0.06 1.11 ± 0.05
6 months 1.11 ± 0.08 1.27 ± 0.04* 1.31 ± 0.07*
SOD (U/g of erythrocytes)
Baseline 889.3 ± 31.2 895.4 ± 22.7 882.8 ± 24.3
6 months 894.5 ± 28.7 904.0 ± 21.2 911.4 ± 29.9
GPx (U/g of erythrocytes)
Baseline 9.57 ± 0.82 9.63 ± 0.56 9.52 ± 0.61
6 months 9.54 ± 0.45 11.25 ± 0.49* 11.85 ± 0.62*
Catalase (KU/g of erythrocytes)
Baseline 12.3 ± 0.8 12.1 ± 0.5 12.8 ± 0.2
6 months 12.4 ± 1.0 12.7 ± 1.0 12.4 ± 0.4M.-H. Lai
J. Clin. Biochem. Nutr.
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or Cr + C + E supplementation, the activity of glutathione
peroxidase were significantly increased (p<0.05) in the
treatment groups compared to placebo (Table 5). The
activity of other antioxidant enzymes, such as superoxide
dismutase and catalase, were not different before and after
Cr or Cr + C + E supplementation (Table 5).
Discussion
Statistically and clinically significant effects were demon-
strated related to daily supplementation of Cr (1000 μg) with
or without vitamins C (1000 mg) and E (800 IU) on TBARS
and TAS in patients with type 2 DM. At the onset of
previous study, plasma TBARS levels in subjects with type
2 DM were significantly higher compared to apparently
healthy subjects (5.41 ± 0.11 vs 2.89 ± 0.10 μmol/L), thus,
apparently confirming the notion that lipid peroxidation
increases in diabetes [31]. This 2.52-μmol/L difference in
TBARS reflects the increased lipid peroxidation noted in
other DM studies [13, 32, 33]. After 6 months supplementa-
tion the mean TBARS levels for the placebo, Cr and
Cr + C + E groups were 5.58, 4.41 and 3.60 μmol/L, respec-
tively, with significant decreases (p<0.05) demonstrated for
the latter two groups. Anderson et al., reported that 6 months
of Cr supplementation (400 μg chromium pidolate) signifi-
cantly reduced plasma TBARS in subjects with type 2 DM
[34]. Our results for the Cr group were similar to analogous
findings of Anderson et al. [34]. Further, the plasma TBARS
levels decreased 19 and 35% for the Cr and Cr + C + E
groups, respectively. The present results also indicate that 6
months of supplementation with Cr in combination with
vitamins C and E may significantly decrease the end
products of plasma lipid peroxidation compared to Cr alone.
It has been proposed that lipid peroxide levels, which are
elevated in DM, are the end products of membrane damage.
These elevated peroxide levels may result from the hyper-
glycemic state, specifically in relation to autoxidation of
plasma glucose and other small autoxidizable molecules
[35], and they are associated with poor metabolic control of
plasma glucose [36]. In diabetes, the vulnerability to oxida-
tive damage may be partly attributed to lower antioxidative
micronutrient status, with this diminution including trace
elements. Impairments in Cr, vitamin C or vitamin E status
are reportedly aggravating factors in the progression of
diabetes [6, 10, 37]. Further, the increase in lipid peroxida-
tion products is associated with insulin perturbations [38,
39]. In this study, the plasma antioxidant levels were verified
using two independent parameters, TBARS and TAS. After
6 months of Cr or Cr + C + E supplementation, the mean
plasma TAS levels had increased significantly (11 and 18%,
respectively) (Table 4). It appears reasonable to suggest,
therefore, that high-dosage supplementation with Cr in
combination with vitamins C and E may be suitable for
treatment of severely hyperglycemic diabetes.
Vitamin E is considered the most important lipid-soluble
exogenous antioxidant in humans. Vitamin C serves as an
antioxidant, directly by scavenging aqueous peroxyl radicals,
and indirectly by regenerating reduced vitamin E [19].
Vitamins C and E defend against the damaging effects of
high oxidative stress owing to nonenzymatic and autoxida-
tive glycosylation, and metabolic stress in persons with
diabetes [20]. Chromium, like vitamin E, has been shown to
protect rats from oxidative damage related to carbon tetra-
chloride exposure [14], and also decreases lipid peroxida-
tions in isolated rat hepatocytes [40]. Hepatic and renal
TBARS were also reduced in hypertensive rats receiving Cr
as polynicotinate [40].
Most Cr nutrition studies have focused on the role of Cr
for prevention of insulin resistance. In Vladeva’s study [41],
they mentioned that insulin resistance index decreased after
a two month application of Cr 30 mg daily in type 2 DM
patients. So they demonstrated that Cr included early in the
complex therapy of diabetes is beneficial in the reduction of
the degree of insulin resistance. In Martin’s study [42], they
found that insulin sensitivity increased after a six month
application of Cr picolinate 1000 μg daily in type 2 DM
patients. They supposed that Cr supplementation in subjects
with type 2 DM improved insulin sensitivity and glucose
control. In our study, the results show a markedly decrease
of blood insulin and insulin resistance index after a six
month supplementation of Cr and Cr combined with vitamin
C and E groups, these results are similar to those mentioned
above. The mechanism of Cr for decreasing the insulin
resistance is analyzed in the light of an improved first phase
of secretion of insulin or facilitated post-receptor insulin
sensibility as a way of potentiating the insulin action [41]. In
addition, in Duman’s study [2], they demonstrated that
chromium through enhance action of insulin at adipocytes
by increasing intracellular triglyceride synthesis and
decreasing extracellular lipid. Thus, it decreases tendency to
extracellular lipid peroxidation, and results in increasing
tendency to plasma TAS. So we suppose that the effect of
antioxidant of Cr could be an important factor for insulin
resistance improvement. In some studies, vitamin C supple-
mentation was provided by systemic infusion in the dose
range of 500–2000 mg, and it was observed that this vitamin
enhanced glucose disposal by enhancing insulin sensitivity
[43]. In another vitro study indicated that vitamin E may
improve insulin action and insulin secretion by protecting
peripheral tissues and β-cells from free radical-mediated
damage [44]. However, in our study, we also found the
T B A R S  v a l u e  s i g n i f i c a n t l y  d e c r e a s e d  i n  C r+C+E  g r o u p
compared to that in Cr alone group, but we did not observe
markedly diminished for the insulin resistance index in
Cr + C + E group compared to Cr group. Thus, we think the
relationship between antioxidant and insulin resistanceAntioxidative and Insulin Resistance Improvement of Cr, Vitamin C and E
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needs further study.
In conclusion, Cr alone and combining Cr with vitamins C
and E supplementation elicited lower levels of plasma
TBARS, blood glucose, HbA1c and insulin resistance index;
higher levels of TAS as well in subjects with type 2 diabetes
mellitus (HbA1C>8.5%) in this study. TBARS value
significantly decreased in Cr + C + E group compared to
that in Cr alone group. However, further investigation is
needed to confirm these encouraging results.
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